Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of ligelizumab in food allergy
2022-502366-25-00Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 11
01
Overview
Phase 3, double-blind, single-arm trial of ligelizumab in food allergy, sponsored by Novartis. Started Aug 2023; status: completed.
02
Drugs
ligelizumab
03
Conditions
food allergy
Beyond the preview
Go deeper on 2022-502366-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502366-25-00.